208 related articles for article (PubMed ID: 27819410)
1. Comparing and evaluating the efficacy of methotrexate and actinomycin D as first-line single chemotherapy agents in low risk gestational trophoblastic disease.
Lee YJ; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
J Gynecol Oncol; 2017 Mar; 28(2):e8. PubMed ID: 27819410
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: A network meta-analysis.
Li J; Li S; Yu H; Wang J; Xu C; Lu X
Gynecol Oncol; 2018 Feb; 148(2):247-253. PubMed ID: 29203174
[TBL] [Abstract][Full Text] [Related]
3. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women.
Uberti EM; Fajardo Mdo C; da Cunha AG; Frota SS; Braga A; Ayub AC
Rev Bras Ginecol Obstet; 2015 Jun; 37(6):258-65. PubMed ID: 26200823
[TBL] [Abstract][Full Text] [Related]
4. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
Lawrie TA; Alazzam M; Tidy J; Hancock BW; Osborne R
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD007102. PubMed ID: 27281496
[TBL] [Abstract][Full Text] [Related]
5. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
Miller CR; Chappell NP; Sledge C; Leath CA; Phippen NT; Havrilesky LJ; Barnett JC
Gynecol Oncol; 2017 Jan; 144(1):125-129. PubMed ID: 27816248
[TBL] [Abstract][Full Text] [Related]
6. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
Alazzam M; Tidy J; Hancock BW; Osborne R; Lawrie TA
Cochrane Database Syst Rev; 2012 Jul; 7(7):CD007102. PubMed ID: 22786502
[TBL] [Abstract][Full Text] [Related]
7. Five-Day Intravascular Methotrexate Versus Biweekly Actinomycin-D in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia: A Clinical Randomized Trial.
Yarandi F; Mousavi A; Abbaslu F; Aminimoghaddam S; Nekuie S; Adabi K; Hanjani P
Int J Gynecol Cancer; 2016 Jun; 26(5):971-6. PubMed ID: 27101581
[TBL] [Abstract][Full Text] [Related]
8. Conservative Chemotherapy in Gestational Trophoblastic Disease: Experience With Etoposide, Methotrexate, and Dactinomycin Chemotherapy.
Byun SW; Park TC; Bae SN
Int J Gynecol Cancer; 2016 May; 26(4):790-5. PubMed ID: 27057813
[TBL] [Abstract][Full Text] [Related]
9. Comparison of MACT and 5Fu+ACT-D chemotherapy regimens in the treatment of low-risk gestational trophoblastic neoplasia.
Wang Y; Miao JW; Wang T; Wang Y; Wu YM; Kong WM; Su L; Duan W
J Chemother; 2016 Apr; 28(2):135-9. PubMed ID: 27105436
[TBL] [Abstract][Full Text] [Related]
10. Single or two drug combination therapy as initial treatment for low risk, gestational trophoblastic neoplasia. A Canadian analysis.
Hoskins PJ; Le N; Kumar A; Pina A; Sabourin JN; Kim H; Osborne RJ
Gynecol Oncol; 2020 May; 157(2):367-371. PubMed ID: 32143915
[TBL] [Abstract][Full Text] [Related]
11. First line chemotherapy in low risk gestational trophoblastic neoplasia.
Alazzam M; Tidy J; Hancock BW; Osborne R
Cochrane Database Syst Rev; 2009 Jan; (1):CD007102. PubMed ID: 19160319
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pulsed actinomycin D and 5-day actinomycin D as first-line chemotherapy for low-risk gestational trophoblastic neoplasia.
Mu X; Song L; Li Q; Yin R; Zhao X; Wang D
Int J Gynaecol Obstet; 2018 Nov; 143(2):225-231. PubMed ID: 30051913
[TBL] [Abstract][Full Text] [Related]
13. A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia.
Shah NT; Barroilhet L; Berkowitz RS; Goldstein DP; Horowitz N
J Reprod Med; 2012; 57(5-6):211-8. PubMed ID: 22696815
[TBL] [Abstract][Full Text] [Related]
14. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia.
Yarandi F; Eftekhar Z; Shojaei H; Kanani S; Sharifi A; Hanjani P
Int J Gynaecol Obstet; 2008 Oct; 103(1):33-7. PubMed ID: 18632105
[TBL] [Abstract][Full Text] [Related]
15. Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens.
Abrão RA; de Andrade JM; Tiezzi DG; Marana HR; Candido dos Reis FJ; Clagnan WS
Gynecol Oncol; 2008 Jan; 108(1):149-53. PubMed ID: 17931696
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
Kang HL; Zhao Q; Yang SL; Duan W
Chemotherapy; 2019; 64(1):42-47. PubMed ID: 31163446
[TBL] [Abstract][Full Text] [Related]
17. Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities.
Matsui H; Iitsuka Y; Seki K; Sekiya S
Gynecol Obstet Invest; 1998; 46(1):5-8. PubMed ID: 9692333
[TBL] [Abstract][Full Text] [Related]
18. An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275.
Schink JC; Filiaci V; Huang HQ; Tidy J; Winter M; Carter J; Anderson N; Moxley K; Yabuno A; Taylor SE; Kushnir C; Horowitz N; Miller DS
Gynecol Oncol; 2020 Aug; 158(2):354-360. PubMed ID: 32460997
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pulsed actinomycin D versus 5-day methotrexate for the treatment of low-risk gestational trophoblastic disease.
Mousavi A; Cheraghi F; Yarandi F; Gilani MM; Shojaei H
Int J Gynaecol Obstet; 2012 Jan; 116(1):39-42. PubMed ID: 21996593
[TBL] [Abstract][Full Text] [Related]
20. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
Mora PAR; Sun SY; Velarde GC; Filho JR; Uberti EH; Dos Santos Esteves APV; Elias KM; Horowitz NS; Braga A; Berkowitz RS
Gynecol Oncol; 2019 May; 153(2):277-285. PubMed ID: 30857648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
